HelloBetter offers ten online therapy programmes addressing depression, insomnia, panic disorders and underserved conditions such as vaginismus and chronic pain. Six programmes have BfArM approval and are fully integrated into Germany’s standard healthcare system as prescription digital therapeutics (DiGA), available free to publicly insured adults; 120,000 patients have used the programmes. The company has conducted 30 randomized controlled trials on its commercial products, most published in peer-reviewed journals, and in 2023 gained FDA approval for a digital therapeutic to treat panic disorders. Founded in 2015, HelloBetter operates across Berlin, Potsdam and Hamburg and employs over 150 professionals. The company launched HelloGina in the US in 2022 to address vaginismus and continues to develop new digital therapeutics. A priority for 2025 is entering the French market through pilots and partnerships with Mutuelles and pursuing regulatory approval by the HAS to secure nationwide reimbursement. HelloBetter provides ten online therapy programs addressing common conditions such as depression, insomnia, and panic disorders, as well as underserved conditions including vaginismus and chronic pain. Six of its programmes have been approved by the German Federal Institute for Drugs and Medical Devices (BfArM) and are integrated into Germany's standard healthcare system. Those approved programmes are available free of charge to publicly insured adults as prescription digital therapeutics. Earlier this year the company launched an AI product, MindFIT, in stealth mode and expects first results next year. HelloBetter has secured €3M in funding to develop and commercialise the AI to personalise user experience and improve adherence, satisfaction, and overall mental health outcomes. HelloBetter offers evidence-based digital therapy courses addressing stress, panic, depression, insomnia, and other mental health challenges. Founded in 2015, the company is a global pioneer in digital mental health research with 33 randomized controlled trials published in peer-reviewed journals. In Germany, six of its ten therapy programs are part of the standard of care and are available free to publicly insured adults as prescription digital therapeutics (DiGA). The company expanded to the U.S. in 2022 under the HelloGina brand with a sexual wellness programme for vaginismus and received FDA 'breakthrough device' designation in early 2023. In 2023 HelloBetter has raised €12M to date, bringing total funding to €25M after a €5M second closing of its A2 round. The new capital will be used to invest in sales, marketing, and data analytics, enter new markets, and further expand its digital therapeutics portfolio. HelloBetter, founded in 2015 as Get.on and based in Hamburg, offers psychological online trainings aimed at the prevention and treatment of mental illnesses. Its core product line comprises digital therapeutics (DTx) delivered via online training programs. The company plans to use new capital to ramp up commercialisation of its DTx products in Germany. HelloBetter also aims to expand its presence across Europe and into the United States. The articles report that investors have now committed a total of around €20 million to the company. HelloBetter develops digital therapeutics (DTx) delivered as software-as-a-medical-device to prevent and treat mental and behavioral health conditions. The platform offers programs targeting burnout, depression in diabetes patients, chronic pain and vaginismus, and has secured universal health-insurance reimbursement for four products in Germany. The company reported a 125% increase in total clients treated from 2020 to 2021. HelloBetter works with health insurers and partners including Barmer, AudiBKK, Allianz, Swica and ratiopharm (a Teva subsidiary), plus over 100 employers. It has joined the Digital Therapeutics Alliance to support further international expansion. The company is focusing on commercialisation in the German market and advancing expansion beyond the DACH region.

Total raised

$35M

Funding rounds

7

Latest round

Equity

Latest activity

Mar 2025